Abivax Reports Positive Long-Term Phase 2b Ulcerative Colitis Data and Q1 2026 Financials

summarizeSummary

Abivax reported positive long-term clinical data for its lead ulcerative colitis drug candidate, obefazimod, showing durable remission and a favorable safety profile, alongside Q1 2026 financial results and an update on its royalty certificate repurchase.

check_boxKey Events

• Positive Long-Term Ulcerative Colitis Data

  Three-year interim data from the Phase 2a/2b trial of obefazimod in ulcerative colitis showed 68% of patients in clinical remission at week 144, with no new safety signals observed over up to seven years of treatment. This supports the drug's potential as a durable treatment option.

• Improved Net Loss in Q1 2026

  The company reported a net loss of €(48.5) million for Q1 2026, an improvement from €(52.4) million in Q1 2025, primarily due to a significant financial gain of €8.0 million from foreign exchange and interest income on invested IPO proceeds.

• Increased R&D and Commercialization Spend

  Research and development expenses increased by €10.2 million to €49.5 million in Q1 2026, reflecting progression in Crohn's disease trials, new indications for obefazimod, and increased manufacturing costs. Sales and marketing expenses also rose by €0.9 million to €1.7 million in preparation for potential U.S. commercial launch.

• Royalty Certificate Repurchase Details

  The company repurchased all outstanding royalty certificates for $90 million (€76.5 million) on May 4, 2026. Half was paid in cash, and the other half was settled by issuing 403,347 ADSs at $111.57 per ADS to the holders, removing a future royalty obligation.

auto_awesomeAnalysis

Abivax announced compelling three-year interim data from its Phase 2a/2b open-label maintenance trial for obefazimod in ulcerative colitis, showing 68% of patients in clinical remission at week 144 with no new safety signals. This strong durability and favorable tolerability profile significantly de-risks the lead candidate ahead of crucial Phase 3 maintenance trial results expected in late Q2 2026 and an NDA submission in Q4 2026. Financially, the company reported an improved net loss for Q1 2026, driven by a substantial financial gain from foreign exchange and invested IPO proceeds, despite increased R&D and sales & marketing expenses as it prepares for potential commercialization. The previously announced repurchase of royalty certificates for $90 million, partially settled by issuing 403,347 ADSs, further strengthens the company's financial structure by removing future obligations. The company maintains a cash runway into Q4 2027, providing stability through upcoming milestones.